TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.

Trial Details

NCT ID
NCT07713732
Phase
PHASE1
Sponsor
Treeline Biosciences, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • TLN-499
  • Venetoclax
Locations (sample)
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • Malvern, Victoria, Australia|-37.86259,145.02811
  • Nedlands, Western Australia, Australia|-31.98184,115.8073

Key Eligibility Criteria

  • Adults ≥18 years of age
  • Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma
  • Measurable disease per RECIST v1.1 or mRECIST
  • ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →